Monitor initial prescription uptake and reimbursement dynamics in Japan over the next 2-3 quarters to gauge revenue contribution. Also watch for potential label expansion updates and ex-Japan regulatory progress for acquired HO.
Price Chart
Executive Summary
Rhythm Pharmaceuticals announced the commercial launch of IMCIVREE (setmelanotide) in Japan for acquired hypothalamic obesity, following MHLW approval and NHI drug price listing. This is the first approved therapy in Japan for acquired HO, with an estimated addressable population of 5,000-8,000 patients. The launch expands Rhythm's global commercial footprint and adds a new revenue stream, though the patient population is relatively small.
Key Facts
- IMCIVREE (setmelanotide) launched commercially in Japan for acquired hypothalamic obesity
- First approved therapy in Japan for acquired HO
- MHLW approval received in August 2026; NHI drug price listing secured
- Phase 3 TRANSCEND trial met primary endpoint with 18.8% placebo-adjusted BMI reduction
- Estimated 5,000-8,000 patients with acquired HO in Japan
- Rhythm has been building its Japan team in preparation for launch
Financial Impact
Commercial launch in Japan opens a new revenue stream for IMCIVREE in an estimated 5,000-8,000 patient population; revenue contribution not disclosed
Risk Factors
- Small addressable patient population (5,000-8,000) limits peak revenue potential
- Competition from other weight management therapies could emerge
- Pricing and reimbursement negotiations may affect commercial uptake
- Safety profile includes serious adverse reactions (adrenal insufficiency, depression, hypersensitivity)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3380291 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | Press Release | $86.71 | awaiting T+60 | — | $89.47 (+3.18%) |
Oct 13, 2026 13d ago | SC 13G | $86.61 | awaiting T+60 | — | $89.47 (+3.30%) |
Sep 14, 2026 6w ago | 144 | $96.77 | awaiting T+60 | — | $89.47 (+7.54%) |
Aug 17, 2026 10w ago | Insider Cluster | $115.25 | awaiting T+60 | — | $89.47 (+22.37%) |
Aug 17, 2026 10w ago | Insider Cluster | $115.25 | awaiting T+60 | — | $89.47 (−22.37%) |
Aug 4, 2026 11w ago | 8-K | $105.78 | awaiting T+60 | — | $89.47 (−15.42%) |
Aug 4, 2026 11w ago | Press Release | $105.78 | awaiting T+60 | — | $89.47 (−15.42%) |
Jul 8, 2026 15w ago | Press Release | $115.48 $92.83 | ▼ −19.61% | ▼ −21.25% | $89.47 (−22.52%) |
Jun 22, 2026 18w ago | 144 | $106.19 $98.01 | ▼ −7.70% | ▼ −10.95% | $89.47 (−15.75%) |
Jun 15, 2026 19w ago | 8-K | $89.72 $102.20 | ▲ +13.91% | ▲ +12.91% | $89.47 (−0.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers